Warning: The NCBI web site requires JavaScript to function. more...
An official website of the United States government
The .gov means it's official. Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.
The site is secure. The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.
Inhibition of TAMRA-FP binding to human ABHD16A expressed in HEK293 cells at 20 to 200 uM preincubated for 1 hr followed by TAMRA-FP addition measured after 1 hr by fluorescence based ABPP analysis
Assay data:1 Tested
SummaryPubMed CitationRelated BioAssays by Target
Inhibition of TAMRA-FP binding to ABHD16A in rat cerebellar membranes at 200 uM preincubated for 1 hr followed by TAMRA-FP addition measured after 1 hr by fluorescence based ABPP analysis
Assay data:1 Active, 1 Tested
SummaryCompounds, ActivePubMed CitationRelated BioAssays by Target
Inhibition of TAMRA-FP binding to ABHD16A in rat cerebellar membranes at 1 uM preincubated for 1 hr followed by TAMRA-FP addition measured after 1 hr by fluorescence based ABPP analysis
Inhibition of TAMRA-FP binding to ABHD16A in rat cerebellar membranes at 10 uM preincubated for 1 hr followed by TAMRA-FP addition measured after 1 hr by fluorescence based ABPP analysis
Assay data:2 Active, 2 Tested
Inhibition of TAMRA-FP binding to ABHD16A in rat cerebellar membranes preincubated for 1 hr followed by TAMRA-FP addition measured after 1 hr by fluorescence based ABPP analysis
Ratio of IC50 for reversible inhibition of human ABHD16A expressed in HEK293 cells to IC50 for inhibition of human ABHD16A expressed in HEK293 cells
Assay data:3 Tested
Inhibition of human ABHD16A expressed in HEK293 cells assessed as residual activity at 100 uM preincubated for 30 mins followed by 1-LG substrate addition and measured after 90 to 120 mins by fluorometric assay relative to control
Assay data:2 Tested
Reversible inhibition of human ABHD16A expressed in HEK293 cells preincubated for 30 mins followed by 40 fold compound dilution and subsequent 1-LG substrate addition and measured at 30 mins time interval for 120 mins by fluorometric assay
Assay data:1 Active, 1 Activity ≤ 1 µM, 3 Tested
SummaryCompounds, ActiveCompounds, activity ≤ 1 µMPubMed CitationRelated BioAssays by Target
Inhibition of human ABHD16A expressed in HEK293 cells preincubated for 30 mins followed by 1-LG substrate addition and measured after 90 to 120 mins by fluorometric assay
Assay data:3 Active, 1 Activity ≤ 1 µM, 3 Tested
Inhibition of human ABHD16A expressed in HEK293 cells assessed as residual activity at 10 uM preincubated for 30 mins followed by 1-LG substrate addition and measured after 90 to 120 mins by fluorometric assay relative to control
Assay data:20 Tested
Potency index, ratio of tetrahydrolipstatin IC50 to compound IC50 for inhibition of ABHD16A (unknown origin)
Inhibition of ABHD16A (unknown origin)
Assay data:4 Active, 4 Activity ≤ 1 µM, 4 Tested
Inhibition of Bat5 in mouse Neuro2a cells at 3 nM after 4 hrs by ABPP-SILAC assay
Inhibition of BAT5 binding to FP-biotin in [12C][14N]-lysine, arginine and [13C6][15N2]-lysine, arginine labeled HEK293T cells at 20 uM after 1 hr by isotopic activity-based protein profiling-MudPIT assay
Late stage assay provider results from the probe development effort to identify inhibitors of diacylglycerol lipase, beta (DAGLb): LCMS-based cell-based Activity-Based Protein Profiling (ABPP) SILAC selectivity analysis for ABHD6
SummaryCompounds, ActivePubMed CitationRelated BioAssays by DepositorRelated BioAssays by Same ProjectRelated BioAssays by Target
Late stage assay provider results from the probe development effort to identify inhibitors of diacylglycerol lipase, beta (DAGLb): LCMS-based cell-based Activity-Based Protein Profiling (ABPP) SILAC selectivity analysis
Late stage assay provider results from the probe development effort to identify inhibitors of PME-1: ABHD10 inhibitor LC-MS/MS-based cell-based ABPP-SILAC assay
Late stage assay provider results from the probe development effort to identify inhibitors of PME-1: LC-MS/MS-based cell-based ABPP-SILAC assay
Late stage assay provider results from the probe development effort to identify inhibitors of pPAFAH: LC-MS/MS-based biochemical ABPP-MudPIT assay to determine selectivity of test compounds in the mouse brain membrane proteome
Late stage assay provider results from the probe development effort to identify inhibitors of LYPLA1: LC-MS-based cell-based SILAC Activity-Based Protein Profiling (ABPP) for anti-target ABHD11
Filters: Manage Filters
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on